Gasherbrum Bio, Inc.

Eli Lilly and Company

Lhotse Bio, Inc

Aconcagua Bio, Inc.

Haizhen Zhang

Hui Lei

Xichen Lin

Qinghua Meng

Andrew Jennings

Wei Huang

Weiqiang Xing

Lian Zhu Liu

Gang Liu

Qiong Zhang

Tianwei Ma

Zhongmiao Xu

Zhi Long Hu

Chunliang Lu

Jingye Zhou

Yuan Tian

Cui Li

Michael Allen Hanson

Xiaoqing Wang

Mi Zeng

Zhe Nie

Ding Xue

Jian Liu

Zhuming Zhang

Eric Therrien

Anatoly Ruvinsky

Evelyne Houang

Anatoly M Ruvinsky

The present disclosure provides compounds for modulating calcitonin receptor and/or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and/or amylin receptor associated disease or disorder.

Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity

The present disclosure provides LPA antagonists, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating LPA-associated diseases, disorders, and conditions.

Compounds and compositions for treating conditions associated with LPA receptor activity

The present disclosure relates generally to GLP-1 agonists and pharmaceutical compositions comprising the same, as well as methods for treating a GLP-1 associated disease, disorder, or condition.

Heterocyclic GLP-1 agonists

This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

This disclosure relates to GLP-1 agonists of Formula I: including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

A compound of the Formula (1) is below provided where R1-R5 are as described in the description and each '*' represents a chiral center. 

Cyclohexyl benzamide compounds

The present invention provides a compound of Formula II wherein X is selected from the group consisting of CH and N; Q is selected from the group consisting of CH3 and H; R is selected from the group consisting of and; or a pharmaceutically acceptable salt thereof, compositions, methods to treat liver disease and NASH. 

Isoquinolin and naphthydrin compounds

The present invention provides a compound of Formula I   or

Cyclobutyl-imidazolidinone compounds

The present invention provides compounds of the Formula below wherein R, R1-R3 are as described herein; methods of treating patients for diabetes using the compounds, and processes for preparing the compounds.

Growing community of inventors

Shanghai, China

Haizhen Zhang